ALB and End Stage Liver Disease: Objective Our objective was to evaluate the CLIF Consortium Acute Decompensation score (CLIF-C AD) for post-bleed risk stratification, using six-week mortality as the prespecified primary endpoint and five-day rebleeding as a prespecified secondary endpoint, in comparison with MELD-Na (Model for End-Stage Liver Disease with sodium) and AIMS65 (albumin, international normalized ratio (INR), mental status, systolic blood pressure, age ≥65 years).